THE PREDICTIVE SIGNIFICANCE OF EOSINOPHILIA IN PERIPHERAL BLOOD IN PATIENTS WITH HODGKIN LYMPHOMA
Abstract
Introduction/Objective: Hodgkin lymphoma (HL) is a rare neoplasm of the lymphatic system and is one of the most common cancers in the young adult population. Histopathologically, 95% of Hodgkin lymphoma is classic Hodgkin lymphoma (cHL). Eosinophilia, both peripherally and in tissues, is relatively common in patients with HL, especially in the nodular sclerosis and mixed cellularity subtypes. Its presence indicates a complex interaction between tumor cells and the immune system. In addition to eosinophilia present in the tissue sample, eosinophilia is also detected in the peripheral blood. The study aimed to analyze HL patients by sex, age, clinical stage, the International Prognostic Score (IPS), and B symptoms, as well as to determine the association between tumor mass size and the complete blood count, erythrocyte sedimentation rate (ESR), the C reactive protein (CRP) level, the clinical stage, and the IPS, with special reference to the significance of eosinophilia in peripheral blood as a predictor of tumor mass size and therapeutic response.
Materials and methods: A retrospective analysis of 58 new cases of HL, diagnosed and treated at the Clinic for Hematology of the University Clinical Center Kragujevac, was performed between December 31, 2018, and December 31, 2023. Data was obtained from written medical records. The initial blood laboratory parameters at diagnosis were analyzed, and the therapeutic response was assessed after the first-line therapy was administered. IBM SPSS Statistics, Version 23, software was used for statistical data processing. Statistical significance was defined at p < 0.05.
Results: At presentation, the observed population had advanced disease – CS III (27.6%) and CS IV (39.7%); B symptoms were present in 76% of the patients, and a high IPS was registered in 48.3% of the subjects. Bulky mediastinal mass was present in 48.3% of patients, while 34.3% of patients presented with nonmediastinal localization. No correlation was found between the leukocyte count, the eosinophil count, the hemoglobin level, the erythrocyte sedimentation rate, CRP values, the clinical stage, IPS, and the maximum diameter of the measured lymph nodes (p > 0.05). However, the analysis showed a statistically significant association between eosinophilia and therapeutic response (p = 0.024), indicating its potential prognostic significance.
Conclusion: Peripheral blood eosinophilia was shown to be a potential predictor of therapeutic response, but not a predictor of tumor mass size. Clinical and radiological diagnostics remain the standard for assessing tumor burden.
References
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013 [Internet]. Bethesda, (MD): National Cancer Institute; 2016 Apr [updated 2016 Sep 12; cited 2025 Dec 15]. Available from: https://seer.cancer.gov/archive/csr/1975_2013/.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th rev. ed. Lyon: International Agency for Research on Cancer; c2017. Chapter 15, Hodgkin lymphomas: p. 423-41.
Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012 Oct;122(10):3439-47. doi: 10.1172/JCI61245.
Fuggle WJ, Crocker J, Smith PJ. A quantitative study of eosinophil polymorphs in Hodgkin's disease. J Clin Pathol. 1984 Mar;37(3):267-71. doi: 10.1136/jcp.37.3.267.
von Wasielewski R, Seth S, Franklin J, Fischer R, Hübner K, Hansmann ML, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000 Feb 15;95(4):1207-13. doi: 10.1182/blood.V95.4.1207.004k34_1207_1213.
Morales-Camacho RM, Caballero-Velázquez T, Borrero JJ, Bernal R, Prats-Martín C. Hematological Neoplasms with Eosinophilia. Cancers (Basel). 2024 Jan 12;16(2):337. doi: 10.3390/cancers16020337.
Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in Cancer: Favourable or Unfavourable? Curr Med Chem. 2016;23(7):650-66. doi: 10.2174/0929867323666160119094313.
Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Perin V, et al. The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol. 1997;8 (Suppl 2):89-96. doi: 10.1093/annonc/8.suppl_2.S89.
Cyriac S, Sagar TG, Rajendranath R, Rathnam K. Hypereosinophilia in hodgkin lymphoma. Indian J Hematol Blood Transfus. 2008 Jun;24(2):67-8. doi: 10.1007/s12288-008-0031-x.
Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. doi: 10.1200/JCO.2008.19.8820.
Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. doi: 10.1200/JCO.2016.70.9410.
Gobbi PG, Cavalli C, Federico M, Bertoloni D, Di Prisco UA, Rossi A, et al. Hodgkin's disease prognosis: a directly predictive equation. Lancet. 1988 Mar 26;1(8587):675-9. doi: 10.1016/s0140-6736(88)91477-8.
Fermé C, Vanel D, Ribrag V, Girinski T. Role of imaging to choose treatment. Cancer Imaging. 2005 Nov 23;5 Spec No A(Spec No A):S113-9. doi: 10.1102/1470-7330.2005.0032.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998 Nov 19;339(21):1506-14. doi: 10.1056/NEJM199811193392104.
Petrović M. Limfomi. In: Čolović M, Janković G, editors. Maligne bolesti krvi. Beograd: Zavod za udžbenike i nastavna sredstva; 1999. p. 303-21.
Colonna P, Jais JP, Desablens B, Harousseau JL, Brière J, Boasson M, et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol. 1996 Jun;14(6):1928-35. doi: 10.1200/JCO.1996.14.6.1928.
Vaughan Hudson B, Linch DC, Macintyre EA, Bennett MH, MacLennan KA, Vaughan Hudson G, et al. Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). British National Lymphoma Investigation. J Clin Pathol. 1987 Mar;40(3):247-50. doi: 10.1136/jcp.40.3.247.
Sjöberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012 Jan 26;119(4):990-6. doi: 10.1182/blood-2010-08-302604.
Herold M, Keinert K, Anger G. Risk Adapted Combined Radio- and Chemotherapy in Hodgkin Disease 10-Year Follow Up. Onkologie 1999 Aug 1;22(4):310-3. doi: 10.1159/000026962.
Simonović O, Stanković I, Pejčić T, Mačukanović Golubović L, Marjanović G. Mediastinal mass as a prognostic factor of Hodgkin lymphoma: Case review. Acta medica Medianae. 2008;47(4):25-8.
Gisselbrecht C, Mounier N, André M, Casanovas O, Reman O, Sebban C, et al. How to define intermediate stage in Hodgkin's lymphoma? Eur J Haematol Suppl. 2005 Jul;(66):111-4. doi: 10.1111/j.1600-0609.2005.00463.x.
Milošević R, Leković D, Antonijević N, Bogdanović A. Eosinophilia as a first sign of Hodgkin's lymphoma: A case report. Vojnosanitetski pregled. 2017;74(6):582-5. doi: 10.2298/VSP150604245M.
